openPR Logo
Press release

An exclusive Aerie Pharmaceuticals speaker interview released for SMi’s Ophthalmic Drugs Conference 2019

09-03-2019 03:27 PM CET | Media & Telecommunications

Press release from: SMi Group Ltd

An exclusive Aerie Pharmaceuticals speaker interview released

SMi Group Reports: Vice President of Aerie Pharmaceuticals to present at SMi’s Ophthalmic Drugs conference commencing on 18th- 20th November 2019 in London
SMi catches up with Aerie Pharmaceuticals Vice President, Chemistry, Mitchell de Long as a speaker for the Ophthalmic Drugs conference taking place on the 18th- 20th November 2019 in London. As Europe’s leading Ophthalmic Drugs conference, the three-day agenda will explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort, and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.

Snapshot of Mitchell’s interview:

The ophthalmic drugs market has matured greatly over recent years, what are the key significant developments you have noticed over the past year?
“The launch in the US of Rocklatan is certainly the most significant new development in the past year, as it marks the first approval by the US FDA of a combination drug containing a prostaglandin analogue (PGA). Also, of note is Allergan’s filing of an NDA in the US for an intracameral implant of bimatoprost, a prostaglandin analogue. This would mark the first time a PGA would be delivered by injection into the eye, as opposed to by an eyedrop. Other novel molecules that have launched in the past few years will also prove interesting as they find their niche in a suddenly more crowded marketplace.”

What do you personally see as the greatest challenge to overcome in the field of Ophthalmic Drugs at the moment?
“Since the last flurry of new ophthalmic drugs was launched, the reimbursement situation in the US has become much more complex and poses a significant challenge to the US launch of new drugs...”

For the full speaker interview, speaker line-up and more content including the latest brochure and past attendees, it is available to download at

Proudly sponsored by:

Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 /

Media enquiries contact Neill Howard +44 (0) 207 827 6164 /

1 Westminster Bridge Road

Conference organisers

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release An exclusive Aerie Pharmaceuticals speaker interview released for SMi’s Ophthalmic Drugs Conference 2019 here

News-ID: 1829317 • Views: 512

More Releases from SMi Group Ltd

Regional CIS Experts to Present at Mobile Deployable Communications 2020
SMi Group Reports: Regional speakers will gather at the 13th Mobile Deployable Communications Conference in Warsaw, Poland on the 30th and 31st January 2020. The 13th annual Mobile Deployable Communications Conference will feature high class presentations by esteemed regional presenters from Poland, Romania, Lithuania and NATO. Register by Monday 30th September to save £400 with the early bird discount. Registrations can be made at: This annual military
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures. Key highlights include: Alternative HPAPI manufacturing technologies to
Exclusive Sanofi R&D speaker interview released for 5th Lyophilization USA Confe …
SMi Group reports: Principal Scientist from Sanofi R&D is set to present at SMi’s 5th Annual Lyophilization 2 Day Conference taking place in Boston on October 23 – 24, 2019. This year’s conference will explore novel and developing technologies that tackle current challenges and push innovation in the world of lyophilization. Bringing together industry leaders, it is a platform to discuss relevant topics that delve into alternative lyophilization approaches, applied statistical
Financial Mechanisms to Ensure Successful Energy from Waste Projects
SMi Reports: With recent news that the Alfanar Group will be investing £1 billion in a number of waste to energy projects in the UK, it comes at a time with the UK government's commitment to “net zero” greenhouse gas (GHG) emissions by 2050. The forecast is that the undisclosed projects will utilise over a million tonnes of waste which would have gone to landfill*. This further bolsters the energy

All 5 Releases

More Releases for Aerie

Ophthalmology Drugs Market Analysis & Forecast 2019| Allergan, Aerie Pharmaceuti …
Los Angeles, United State, April 18, 2019, - The report on the global Ophthalmology Drugs market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers, restraints, and opportunities. It sheds light on key production, revenue, and consumption trends so that players could improve their sales and growth in the Global Ophthalmology Drugs Market. It offers a detailed analysis of the competition and
Ophthalmology Drugs Market Competitive Share & Forecast 2019| Allergan, Aerie Ph …
Los Angeles, United State, April 8, 2019- The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Ophthalmology Drugs market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Ophthalmology Drugs Market. We have provided deep analysis of
2023 Projections: Glaucoma Treatment Market Report for Allergan, Pfizer, Novarti … offers 2018 report on Global Glaucoma Treatment market that evaluates industry growth trends through historical data and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2023. According to Azoth Analytics research report Global Glaucoma Treatment Market: Analysis By Indication, By Drug Class, By Sales Channel, By Region, By Country (2018 Edition): Forecast to 2023 - By Indication
Intimate Apparel Market Is Booming Worldwide | L Brands, Hanes Brands, American …
HTF MI released a new market study on Global Intimate Apparel Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates
Industry news with an exclusive interview from Aerie Pharmaceuticals for Ophthal …
SMi are delighted to have interviewed Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals regarding his thoughts and experiences within the ophthalmology space. Mitchell A. (Mitch) deLong holds the position of Vice President, Chemistry at Aerie Pharmaceuticals as well as Adjunct Professor of Chemistry at Duke University. Since Mitch helped to found Aerie as a Duke University spinout in 2005, Aerie has filed 5 INDs and 2 NDAs, with its first
SMi Group: Hear From Boehringer Ingelheim, Novaliq, Santen, Shire, Aerie Pharmac …
Here's a quick update on the key industry experts to network with and about their topics. - Dr. Naj Sharif is the Executive Director in R&D, Head, Global Alliances & External Research, at Santen Inc. He has been in the pharmaceutical industry for over 30 years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Parke-Davis/Warner-Lambert (Pfizer), Syntex